Conjugated estrogens - Pfizer

Drug Profile

Conjugated estrogens - Pfizer

Alternative Names: Premarin

Latest Information Update: 14 Jan 2014

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer; Wyeth
  • Class Estradiol congeners; Hormonal replacements; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyspareunia; Menopausal syndrome; Postmenopausal osteoporosis
  • Clinical Phase Unknown Alzheimer's disease

Most Recent Events

  • 14 Jan 2014 Launched for Menopausal syndrome in World (PO)
  • 14 Jan 2014 Launched for Postmenopausal osteoporosis (prevention) in World (PO)
  • 14 Mar 2012 Pfizer completes a phase I bioequivalence trial of a new formulation in healthy volunteers in Japan (NCT01436513)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top